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OBJECTIVES The aim of this study was to describe long-term outcome in patients with apical hypertrophic
cardiomyopathy (ApHCM) followed in a tertiary referral center.
BACKGROUND Apical hypertrophic cardiomyopathy is a relatively rare form of hypertrophic cardiomyopathy
(HCM), first described in Japan. Initial reports, based on a limited number of patients,
emphasized the benign nature of this condition.
METHODS A retrospective study of 105 patients with ApHCM diagnosed at the Toronto General
Hospital from 1975 to 2000 was performed. Symptoms, clinical findings, mortality and
cardiovascular morbidity were analyzed.
RESULTS The mean age at presentation was 41.4 14.5 years. During a mean follow-up of 13.6 8.3
years from presentation, cardiovascular mortality was 1.9% (2/105) and annual cardiovascular
mortality was 0.1%. Overall survival was 95% at 15 years. Thirty-two patients (30%) had one
or more major morbid events, the most frequent being atrial fibrillation (12%) and myocardial
infarction (10%). Probability of survival without morbid events was 74% at 15 years. Three
predictors of cardiovascular morbidity were identified: age at presentation 41 years, left
atrial enlargement, and New York Heart Association (NYHA) class II at baseline.
Forty-four percent of the patients were asymptomatic at the time of last follow-up.
CONCLUSIONS Apical hypertrophic cardiomyopathy in North American patients is not associated with
sudden cardiac death and has a benign prognosis in terms of cardiovascular mortality.
Nevertheless, one third of these patients experience serious cardiovascular complications, such
as myocardial infarction and arrhythmias. These data are likely to influence the counseling
and management of patients with ApHCM. (J Am Coll Cardiol 2002;39:638–45) © 2002
by the American College of Cardiology
Hypertrophic cardiomyopathy (HCM) is an autosomal
dominant disease of the myocardium, caused by mutations
in one of nine genes encoding sarcomeric proteins (1,2) and
characterized by marked variability in morphological ex-
pression and natural history (3,4). Apical hypertrophic
cardiomyopathy (ApHCM) is a relatively rare form of
HCM, in which the hypertrophy of myocardium predom-
inantly involves the apex of the left ventricle (LV) (5,6). The
typical features of ApHCM, first described by Sakamoto (5)
and Yamaguchi (6) and their associates, consist of “giant” T
wave negativity in the electrocardiogram (5) and a “spade-
like” configuration of the LV cavity at end-diastole on left
ventriculography (6).
Studies of ApHCM in the Japanese population have
indicated a benign prognosis in patients with this condition
(5–8), with the exception of elderly patients (9). A less
favorable outcome was initially reported from non-Japanese
patients with all forms of HCM (10) and with ApHCM, in
particular (11). More recent studies have found ApHCM to
be associated with a rare occurrence of cardiovascular
mortality and morbidity even in the Western population
(12,13). However, severe clinical manifestations, including
sudden cardiac death, severe arrhythmias and apical infarc-
tion with apical aneurysm, have frequently been described in
case reports (14–20). Because the majority of long-term
follow-up studies from non-Asian centers are based on
small numbers of patients (11–13,21–25), the long-term
prognosis of ApHCM in non-Japanese patients remains
poorly defined. Therefore, this study was undertaken to
investigate the clinical manifestations and the long-term
mortality and morbidity in 105 patients with ApHCM,
diagnosed in a large tertiary care referral center’s HCM
clinic.
METHODS
Study population and study design. The study subjects
were identified through a registry of the HCM Clinic at the
Toronto General Hospital, the University Health Network,
which serves as a large tertiary referral center. We studied
the clinical outcome of 105 consecutive patients with a
diagnosis of ApHCM seen in the HCM clinic between
January 1975 and December 2000. Data were abstracted on
demographic characteristics, coronary risk factors, family
history of HCM, symptoms and findings at physical exam-
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ination at the time of presentation and diagnosis of
ApHCM, as well as at the most recent follow-up. In
addition, the results of electrocardiogram (ECG), echocar-
diography, ambulatory ECG monitoring and cardiac cath-
eterization were reviewed. Twenty-six patients in this study
were included in a previous report on ApHCM from this
institution (13). The study was approved by the Research
Ethics Board of the Toronto General Hospital.
Diagnostic criteria. The diagnostic criteria for ApHCM
included demonstration of asymmetric left ventricular hy-
pertrophy (LVH), confined predominantly to the LV apex
with an apical wall thickness 15 mm and a ratio of
maximal apical to posterior wall thickness 1.5, based on
two-dimensional echocardiography (echo) or MRI. Patients
with ApHCM according to the previously stated criteria
were further subdivided into two groups based on whether
they had isolated asymmetric apical hypertrophy—“pure”
ApHCM—or had a coexistent hypertrophy of the inter-
ventricular septum—“mixed” ApHCM. Patients with the
“mixed” ApHCM pattern had to demonstrate the greatest
wall thickness in the apical segments.
Follow-up. Late follow-up was obtained by direct contact
with patients, their physicians or by clinic chart review.
Additional medical records were obtained to confirm the
timing and presence of cardiovascular complications.
Definition of mortality and morbidity. Mortality was
classified as cardiovascular in origin if it was secondary to
one of the following: myocardial infarction, intractable
arrhythmia, congestive heart failure or stroke. Major morbid
events included 1) atrial fibrillation or flutter, 2) sustained
ventricular tachycardia (VT), defined as 30 consecutive
ventricular beats or associated with hemodynamic instabil-
ity, 3) ventricular fibrillation, 4) myocardial infarction, 5)
stroke or transient ischemic attack, or 6) congestive heart
failure. The diagnosis of myocardial infarction was estab-
lished in the presence of characteristic symptoms, typical
pattern on ECG and elevated cardiac enzymes, or by the
appearance of a definite new wall motion abnormality on
echocardiography, MRI or left ventricular angiography, in
association with changes in ECG.
Electrocardiography. The initial and the most recent
ECG were analyzed for the presence of LVH using the
Sokolow-Lyon criteria (26). The corrected QT interval was
measured in lead V2 (27). “Giant” T wave negativity was
defined as a voltage of negative T wave 1 mV (10 mm)
in any of the leads. Maximum T wave inversion from any of
the leads V3, V4, V5 or V6 and the sum of T wave amplitude
in these leads in the initial and the most recent ECG were
compared. Time-related changes in T wave amplitude were
analyzed at mid-term (4 and 8 years) and long-term
(8 years) follow-up. In the presence of an apical infarction,
the last ECG before the infarction was used for comparison
with the initial ECG tracing.
Echocardiography. Doppler echo studies were performed
using commercially available ultrasound equipment. Left
atrial dimension at end-systole and standard left ventricular
dimensions at end-diastole and end-systole, as well as LV
wall thickness were obtained from two-dimensional images
according to the standards of the American Society of
Echocardiography (28). The maximal apical wall thickness
was obtained from the standard apical four- and two-
chamber views at end-diastole. These views were available
in all of our patients and used for comparisons throughout
the follow-up. Doppler recordings of blood velocity at the
apical, midventricular and outflow tract level were per-
formed. Left atrium was considered enlarged if the left atrial
diameter was40 mm. We compared the results of the first
and the most recent echo in patients who did not have any
signs of myocardial infarction and in whom the interval
between the two examinations was 4 years.
Ambulatory ECG monitoring. In 86 patients, all available
ambulatory ECG monitoring covering at least a 24-h period
was reviewed for the occurrence of non-sustained ventricu-
lar tachycardia (NSVT), defined as a minimum of three
consecutive ventricular beats with a rate of 100 beats/min.
Radionuclide studies. Exercise myocardial perfusion im-
aging using either thallium-201 or technetium-99m-
sestamibi was performed in 75 patients. In 24 patients, the
results of myocardial scintigraphy and coronary angiography
were compared.
Angiography. Forty-two patients underwent selective cor-
onary and LV angiography for symptoms of myocardial
ischemia. The procedure included the evaluation of epicar-
dial coronary artery disease, presence of a “spade-like”
configuration on left ventriculogram, and the assessment of
outflow tract obstruction at rest or with provocation (iso-
proterenol, extrasystoles, amyl nitrite).
Statistics. Continuous data are presented as the mean and
one standard deviation (SD). Differences between groups
were analyzed by unpaired or paired t tests, Fisher’s exact
test or the chi-square test, where appropriate. Longitudinal
data were analyzed by Kaplan-Meier estimate (29). Infor-
mation on survival of an age- and gender-matched Ontario
population without ischemic heart disease, obtained from
the Central East Health Information Partnership, Canada,
was used for a qualitative comparison with our study
patients. The time to death or a morbid event was calculated
as the difference between the date of presentation and the
Abbreviations and Acronyms
AF  atrial fibrillation
ApHCM  apical hypertrophic cardiomyopathy
ECG  electrocardiogram
echo  echocardiography
HCM  hypertrophic cardiomyopathy
LV  left ventricle
LVH  left ventricular hypertrophy
NSVT  non-sustained ventricular tachycardia
NYHA  New York Heart Association
VT  ventricular tachycardia
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event date. In patients with multiple morbid events, only the
time to the first event was entered into analysis.
Univariate predictors with a significance level of 0.1
were entered into multivariate Cox proportional hazards
model using a backwards elimination algorithm. A p value
0.05 was considered significant. Statistical analyses were
performed using Stat View (version 4.5, Macintosh; Abacus
Concepts, Berkeley, California) and SPSS for Windows
(version 10, SPSS Inc., Chicago, Illinois).
RESULTS
Baseline
Clinical characteristics. The 105 patients with a diagnosis
of ApHCM represented approximately 7% of all HCM
cases in our center. There were no patients of Japanese
origin in the study population. Clinical and demographic
variables at baseline are presented in Table 1. Eighty-six
patients (82%) were between 20 and 59 years of age, and
only 12 patients (11%) were 60 years or older at the time of
presentation. Although 26% of patients had a history of
treated hypertension, the blood pressure was well controlled.
There was a delay between the initial presentation to a
primary care provider and the final diagnosis of ApHCM,
usually caused by interpretation of ECG changes as signs of
coronary artery disease or athlete’s heart.
A total of 57 patients (54%) were symptomatic at the first
presentation. The main symptoms were angina (16%),
atypical chest pain (14%), palpitations (10%), dyspnea (6%)
and presyncope/syncope (6%). In 17 of these 57 symptom-
atic patients, the first manifestation was a morbid event
including AF (n  10), myocardial infarction (n  5),
exercise-induced ventricular fibrillation (n 1) and conges-
tive heart failure (n  1). Two patients with AF presented
with concomitant embolic events (transient ischemic attack/
stroke). The remaining 48 asymptomatic patients (46%)
presented with incidental findings, such as an abnormal
ECG (n  41), a new undiagnosed murmur (n  3),
abnormal echocardiography performed during evaluation
for other reasons (n  2) or screening for a family history of
HCM (n  2).
Electrocardiography. The analyses of initial ECG record-
ings are presented in Table 1. The maximal T wave
negativity was most frequently seen in lead V4 (n  41),
followed by V5 (n  35) and V3 (n  13). “Giant” T wave
negativity, with mean value 14.4  4.3 mm, was seen in 49
patients (47%). There was no difference in age or history of
hypertension between patients with and without “giant” T
waves. The mean value of T wave negativity for the
remaining patients was 5.6  2.2 mm. There was no
significant difference in distribution of ECG abnormalities
between the “pure” and the “mixed” ApHCM on initial
ECG. There was a weak correlation between the degree of
apical thickness and both the maximal T wave negativity
(r  0.231, p  0.018) and the sum of T wave amplitudes
in precordial leads (r  0.269, p  0.006). No significant
correlation was found between the maximal T wave nega-
tivity and other echocardiographic variables, e.g., the septal
thickness or the ratio of apical to septal thickness.
Echocardiography. The echocardiographic variables at
baseline are presented in Table 1. No patient had left
ventricular outflow tract obstruction, either at rest or fol-
lowing provocative maneuvers. There were 89 patients
(85%) with the “pure” form of ApHCM, with hypertrophy
limited to the apical portion of LV, and 16 patients (15%)
with the “mixed” form of ApHCM, with extension of the
hypertrophy beyond the apical segments. The “mixed”
group demonstrated a significantly worsened functional
NYHA class, as well as increased interventricular septum,
posterior wall and apical thickness (p  0.05) at baseline.
There were no significant differences in length of follow-up,
blood pressure, age, gender, presence of coronary risk factors
or family history between the “pure” and the “mixed” forms
of ApHCM.
The final diagnosis of ApHCM was established using
echo in 96 patients (91%), although in 14 patients (13%) the
initial suspicion of ApHCM occurred during left ventricu-
lography, performed for other reasons before an echo
examination, and by MRI in 9 patients (9%). The nine
patients who were diagnosed by MRI scan all had a “pure”
ApHCM and an initially non-diagnostic echo study. When
echo was repeated to look specifically for ApHCM, echo
confirmed the diagnosis in all nine patients.
Table 1. Baseline Characteristics of the Study Population
Men/women 78/27
Age at presentation (yrs) 41.4  14.5
Age at diagnosis (yrs) 46.1  15.1
Family history of HCM 23 (22%)
Family history of SCD 10 (10%)
History of hypertension 27 (26%)
ECG
LVH signs 68 (65%)
T wave inversion 98 (93%)
Giant T waves 10 mm 49 (47%)
Max T wave inversion (mm) 9.9  5.6
Normal ECG 6 (6%)
QTc interval (ms) 445  80
Echo
IVS thickness (mm) 12.3  3.3
PW thickness (mm) 10.6  1.5
Apical thickness (mm) 19.0  3.1
Ratio apical/PW thickness 1.8  0.3
LV end-diastolic diameter (mm) 48.3  5.2
LV end-systolic diameter (mm) 30.2  5.5
Fractional shortening (%) 37.5  9.2
LA end-systolic diameter (mm) 41.0  5.9
NYHA class I/II/III and IV 64/41/0
S4 audible/palpable 63 (60%)/34 (32%)
Systolic/diastolic blood pressure (mm Hg) 132  21/78  11
Data presented as number (%) or mean  1 SD.
ECG  electrocardiogram; HCM  hypertrophic cardiomyopathy; IVS 
interventricular septum; LA  left atrial; LV  left ventricular; LVH  left
ventricular hypertrophy; Max  maximum; NYHA  New York Heart Association;
PW  posterior wall; QTc  corrected QT interval; SCD  sudden cardiac death;
S4  fourth heart sound.
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Follow-up
Mortality. The mean follow-up from the time of presen-
tation was 13.6 8.3 years (median 12.9, range 0.2 to 32.2)
and from the time of diagnosis was 8.8  6.1 years (median
7.8, range 0.1 to 24.7). Eleven patients died during follow-
up; thus, the overall mortality in this study was 10.5%.
There were nine noncardiac deaths and two cardiovascular
deaths, one caused by myocardial infarction and another
caused by congestive heart failure, consistent with a cardio-
vascular mortality of 1.9% and an annual cardiovascular
mortality of 0.1%. Figure 1 shows Kaplan-Meier estimates
of overall survival since presentation for patients with
ApHCM in comparison to an age- and gender-matched
Ontario population.
Major morbidity. There were 40 morbid cardiovascular
events, AF (n  13), myocardial infarction (n  11),
congestive heart failure (n  5), transient ischemic attack
(n  4), stroke (n  3), VT (n  3) and ventricular
fibrillation (n 1). These morbid events occurred in 32/105
patients (30%). Kaplan-Meier event-free survival curve for
patients without any major cardiac morbidity is shown in
Figure 2. Seventeen patients (16%) presented with a morbid
event. There was no significant association between mor-
bidity and gender, history of hypertension, “pure” or
“mixed” type of ApHCM, apical wall thickness, apical to
posterior wall thickness ratio or “giant” T wave negativity
when tested by a univariate Cox regression analysis. Age at
presentation 41 years, left atrial enlargement and NYHA
class II at baseline were significantly associated with
higher risk for cardiovascular morbidity by a univariate Cox
regression analysis, and all three were also found to be the
independent predictors of cardiovascular morbidity by a
multivariate Cox regression analysis: age at presentation
41 years with Hazard ratio 4.8 (95% CI 2.0 to 11.7), left
atrial enlargement Hazard ratio 3.0 (95% CI 1.4 to 6.6), and
NYHA class II at baseline Hazard ratio 3.4 (95% CI 1.5
to 7.6) (p  0.05).
Thirteen patients (12%) developed AF during follow-up.
A univariate Cox regression analysis identified left atrial
enlargement at baseline as the only predictor of AF (Hazard
ratio 6.5, p  0.017).
Eleven patients (10%) suffered a myocardial infarction,
which was apical in location in nine patients. The degree of
wall motion abnormality varied from a large apical aneurysm
to apical hypokinesis. Four patients suffered an asymptom-
atic apical infarction. The development of myocardial in-
farction was usually associated with a loss of “giant” T wave
negativity, development of new pathological Q waves,
decrease in R wave amplitude, ST elevation or a new RBBB
(one patient). Coronary angiography was performed in 10 of
the 11 patients with infarction, showing normal coronary
arteries in 9 patients and concomitant coronary artery
disease in only 1 elderly patient, who subsequently died of
congestive heart failure. We identified age 41 years at the
time of presentation (Hazard ratio 12, p  0.005) as a
predictor of myocardial infarction. During follow-up, one
patient with a large apical aneurysm and normal coronary
arteries underwent a surgical aneurysmectomy eight years
after infarction for management of recurrent VT.
Seven patients suffered stroke or transient ischemic attack
Figure 1. Kaplan-Meier plot of overall survival since initial presentation of 105 patients with apical hypertrophic cardiomyopathy (ApHCM) (solid line)
in comparison to an age- and gender-matched Ontario population (Ontario) (dotted line). Probability of survival  1 standard error at 15, 20 and 25 years
of follow-up are shown.
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during follow-up. A univariate Cox regression analysis
identified only two significant predictors of cerebrovascular
events, LA size (Hazard ratio 1.2, p  0.005) and presence
of AF (Hazard ratio 5.5, p  0.026).
Clinical findings at follow-up. Forty-four percent of the
patients were asymptomatic at the last follow-up, whereas
56% reported symptoms such as dyspnea on exertion (38%),
palpitations (21%), typical angina (18%), atypical chest pain
(14%), presyncope (10%) and syncope (6%). At the last
follow-up, 62 patients were in NYHA functional class I, 35
patients in class II, 7 patients in class III and 1 in class IV.
Twenty-one of 105 patients (20%) deteriorated in their
functional class; 70 patients (66%) were unchanged, and 14
patients (14%) improved by one class.
The analysis of all available Holter monitor recordings
revealed single or multiple short runs of NSVT with a mean
7  5 beats at a mean heart rate of 146  41 beats/min in
20 out of 86 monitored patients (23%). Only one patient
was symptomatic with syncopal episodes associated with
NSVT.
Forty-four patients (42%) did not take any cardiac med-
ications at the last follow-up, while the remaining patients
were on beta blockers (n  30), calcium channel blockers
(n  34) or antiarrhythmic therapy (n  13).
ECG and echocardiography. Two patterns of ECG
changes during midterm (4 to 8 years) and long-term (8
years) follow-up were observed (Table 2). In patients
presenting with “giant” T wave negativity (10 mm), a
statistically significant decrease in the maximum T wave
amplitude was seen (p  0.05). In contrast, in patients
presenting with “non-giant” T waves, there was a significant
increase in the sum of negative precordial T waves (p 
0.027). Furthermore, five patients presenting with only
minor T wave changes developed “giant” T wave negativity
during follow-up.
Long-term changes in echocardiographic variables are
Figure 2. Kaplan-Meier analysis of freedom from major cardiac morbidity with probability of event-free survival  1 standard error at 5, 10, 15, 20 and
25 years of follow-up are shown.
Table 2. Changes in ECG Variables During Mid-Term and Long-Term Follow-up
Baseline Mid-Term p Value Baseline Long-Term p Value
Giant T wave at baseline
Follow-up (yr) 6.0  1.3 11.9  4.0
Patients (n) n  16 n  20
Maximum T wave (mm) 15.6  5.3 11.7  5.2 0.003 13.5  4.2 10.5  5.5 0.036
Sum of T waves (mm) 43.7  18.1 34.9  14.5 0.029 37.7  14.4 28.7  15.7 0.051
Non-giant T wave at baseline
Follow-up (yr) 5.3  1.7 16.0  5.8
Patients (n) n  15 n  23
Maximum T wave (mm) 5.4  5.9 4.7  3.2 0.62 4.3  2.9 6.1  4.1 0.056
Sum of T waves (mm) 8.8  15.9 9.5  19.9 0.86 8.4  11.1 16.1  14.3 0.027
Data presented as number or mean  1 SD.
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summarized in Table 3. There was a significant increase in
LV diastolic and systolic dimensions and left atrial diameter
during follow-up.
Radionuclide studies. Thirty-nine of 75 patients (52%),
who underwent myocardial scintigraphy had abnormal
scans, showing reversible perfusion defects in 28 patients,
fixed defects in 4 patients and both reversible and fixed
defects in 7 patients. In 32 of 39 cases the apical segment
was involved, showing either reversible (27 patients) or fixed
(5 patients) perfusion defects. There was no difference in the
apical thickness and the magnitude of T wave negativity
between patients with and without abnormal perfusion scan.
Angiography. During follow-up, 42 patients underwent
selective coronary and LV angiography for symptoms of
myocardial ischemia. A “spade-like” configuration of the
LV cavity at end-diastole on left ventriculogram was present
in 29 of 42 patients (69%). A significant epicardial coronary
artery lesion of 50% was detected in eight patients, and
compression of coronary arteries was observed in three
patients. Thus, 31 patients (74%) had no evidence of
coronary artery disease on coronary angiography, despite
symptoms suggesting myocardial ischemia. No significant
LVOT gradient was detected at rest. Twenty-four patients
underwent both coronary angiography and myocardial scin-
tigraphy scans. Nineteen of these patients (79%) had ab-
normal myocardial scintigraphy scans. In 10 patients (53%)
with abnormal perfusion scan and all patients with normal
scan, the coronary arteries were normal.
DISCUSSION
In the present study, we characterized clinical findings,
mortality and morbidity in, to the best of our knowledge,
the largest reported North American series of patients with
ApHCM. ApHCM was first described in Japan (5,6),
where it represents 13% to 25% of the entire HCM
population (7,10,30–32). Outside Japan, ApHCM is less
common and has been reported in 3% to 11% of all HCM
patients (3,10,12,33).
Outcome and prognosis in patients with ApHCM. Our
study showed a benign long-term prognosis in the North
American patients with ApHCM in terms of cardiovascular
mortality. The probability of survival during the first 15
years of follow-up for patients with the apical form of HCM
was similar to the age- and gender-matched Ontario pop-
ulation. There was no sudden cardiac death during follow-
up, and long-term cardiovascular mortality for ApHCM in
our study was 1.9% with an annual mortality of 0.1%. This
is lower than the annual mortality of 1.4% for the entire
HCM spectrum in a nonreferral-based patient population
recently reported by Maron et al. (34) and the cardiovascular
annual mortality of up to 4% previously reported from other
tertiary referral centers (3,35). Furthermore, our results are
similar to those reported from Japan, where ApHCM is
usually associated with a good prognosis (7,8,32), often
better than in other forms of HCM (31). In addition, the
presence of “giant” T wave inversion in the Japanese HCM
patients has been identified as a predictor of favorable
outcome (31). In contrast, the initial, small North American
study reported more serious clinical course with 28% mor-
tality in patients with ApHCM (11). However, their study
population differed significantly with regard to the magni-
tude of T wave negativity and LV configuration, both from
the Japanese (5,6) and the other Western ApHCM patients
including our cohort (12,13,22,23).
The most frequent morbid events in our study were AF
and myocardial infarction. Atrial fibrillation occurred in
12% of the patients. Left atrial enlargement on the baseline
echo was identified as the only predictor of AF. Impaired
LV relaxation in patients with HCM, including ApHCM,
has been previously proposed as a mechanism for progres-
sive left atrial enlargement and subsequent AF (3,13).
Apical myocardial infarction in the presence of normal
coronary arteries was found in about 10% of our patients.
The mechanisms responsible for ischemia in ApHCM are
still unclear, although there is some evidence of a limitation
in coronary flow reserve (21). Decreased capillary myocar-
dial ratio, small vessel disease and other mechanisms (3,32)
may also result in regional apical ischemia and be involved
in development of apical infarction and aneurysm. Apical
segmental dysfunction with midventricular obstruction has
been previously described as a typical wall motion abnor-
mality seen in 11% of patients with ApHCM (32). We
found various degrees of abnormal apical segments, ranging
from a large apical aneurysm requiring surgical removal to
apical hypokinesis.
Presentation. The clinical characteristics of our study pop-
ulation were similar to those described by Japanese and
other investigators, with similar age at presentation
(5,12,13,23), male predominance (7,12,21,23), a high per-
centage of asymptomatic patients (7,8,21), “giant” T wave
negativity in the ECG (5) and a “spade-like” LV configu-
ration at end-diastole (6). As previously described (6,7,13),
a fourth heart sound, reflecting impaired LV relaxation, is
not only frequently audible but also palpable, as shown in
the present study. Thus the phenotypic expression of
ApHCM in the North American patients seems identical to
that seen in the Japanese patients with this form of HCM.
Table 3. Changes in Echocardiographic Variables in 44 Patients
With Apical Hypertrophic Cardiomyopathy During a Mean
Follow-Up of 9.0  4.6 Years
Echocardiographic Variable Baseline Follow-Up p Value
LV end-diastolic diameter (mm) 48.0  5.9 51.2  6.2 0.001
LV end-systolic diameter (mm) 29.2  7.0 30.9  6.9 0.045
Fractional shortening (%) 39.5  11.0 39.9  8.9 0.83
IVS thickness (mm) 12.2  3.5 12.6  3.5 0.27
PW thickness (mm) 10.3  1.4 10.6  1.4 0.40
Apex thickness (mm) 19.0  3.4 19.2  4.6 0.77
LA end-systolic diameter (mm) 40.9  6.8 43.7  6.8 0.001
Mean  1 SD.
IVS  interventricular septum; LA  left atrial; LV  left ventricular; PW 
posterior wall.
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Diagnosis. The correct diagnosis of this form of HCM is
of major importance because many of these patients present
at a relatively young age with chest pain and dramatic T
wave inversions that frequently result in hospitalization for
suspected coronary artery disease. The use of echocardiog-
raphy in the diagnosis of HCM has been widely recognized
(36); however, adequate visualization of the LV apex may be
difficult, and measurements of the apical thickness are
subject to variability depending on the echocardiographic
view (37). In our study, echo established a correct diagnosis
in 91% of the patients and failed to initially diagnose
ApHCM in nine patients in whom MRI clearly demon-
strated asymmetric hypertrophy of the apical LV segment.
The recent study by Pons-Llado et al. (38) showed that
MRI allowed better overall assessment of the degree and
extent of LVH in HCM patients than did echo. The apical
segment was adequately visualized in all patients by MRI
but only in 60% of the patients by echo (38). Furthermore,
MRI allows the early diagnosis of ApHCM by identifying
even a small quantity of hypertrophied myocardium in
different apical locations in a “non-spade” variety of
ApHCM (39). The recent development of intravenous
contrast agents for echocardiographic image enhancement
may improve the diagnostic accuracy of echo in patients
with ApHCM (40). Therefore, in patients with suspicion of
ApHCM and inadequate echo images, the use of contrast
echocardiography or MRI should be considered.
CONCLUSIONS
Apical hypertrophic cardiomyopathy in North American
patients is very similar, if not identical, to that in Japanese
patients, is not associated with sudden cardiac death and has
a benign prognosis in terms of cardiovascular mortality.
However, one third of ApHCM patients may develop
unfavorable clinical events and potentially life-threatening
complications, such as myocardial infarction, arrhythmias,
and stroke. Despite this significant morbidity, the majority
of patients do not show any deterioration in their functional
class, and approximately half remain totally asymptomatic
during follow-up. These data are likely to influence the
counseling and management of patients with ApHCM.
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